Comparative Pharmacology
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus SKELID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus SKELID.
ETIDRONATE DISODIUM vs SKELID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, suppressing crystal dissolution and reducing bone turnover.
SKELID (tiludronate disodium) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity and recruitment.
Paget disease: 5-10 mg/kg/day orally, given as a single dose or divided every 12 hours, for up to 6 months; or 300 mg intravenously over at least 2 hours daily for 3 days. Heterotopic ossification: 20 mg/kg/day orally for 2 weeks pre- and 12 weeks post-surgery. Hypercalcemia of malignancy: 7.5 mg/kg intravenously over 4 hours daily for 3-7 days.
400 mg (2 tablets) orally once daily, taken on an empty stomach at least 2 hours before or after food, for 2 hours with 8 oz plain water; avoid other beverages, food, and medications for 2 hours post-dose.
None Documented
None Documented
Terminal half-life: 1-6 hours after single dose; prolonged to up to 2 weeks in bone due to slow release from hydroxyapatite.
Terminal elimination half-life: 10-12 hours (prolonged in renal impairment; no dose adjustment required for mild-moderate impairment but contraindicated in severe impairment [CrCl <30 mL/min])
Renal: 30-50% of absorbed dose excreted unchanged in urine; biliary/fecal: minimal, with approximately 5% excreted in feces.
Renal: 50-60% unchanged drug; biliary/fecal: <5%
Category C
Category C
Bisphosphonate
Bisphosphonate